Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 18/20 | 0.49 |
| ▸ | F10 | P00742 | 16/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 15/20 | 0.49 |
| ▸ | F2 | P00734 | 14/20 | 0.49 |
| ▸ | F3 | P13726 | 12/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 10/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 10/20 | 0.48 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7149477 | 1.00 | F7 (0.49) | F7F10PRSS1F2F3 | |
| SCHEMBL7149825 | 0.95 | F7 (0.51) | F7F10PRSS1F2F3 | |
| SCHEMBL7141500 | 0.95 | F7 (0.51) | F7F10PRSS1F2F3 | |
| SCHEMBL7141495 | 0.95 | F7 (0.51) | F7F10PRSS1F2F3 | |
| Hydrochloric Acid SCHEMBL7141830 | 0.94 | F7 (0.50) | F7F10PRSS1F2F3 | |
| SCHEMBL7141690 | 0.89 | F7 (0.58) | F7F10PRSS1F2F3 | |
| SCHEMBL7139643 | 0.89 | F7 (0.58) | F7F10PRSS1F2F3 | |
| SCHEMBL7139637 | 0.89 | F7 (0.58) | F7F10PRSS1F2F3 | |
| SCHEMBL7148941 | 0.89 | F7 (0.47) | F7F10PRSS1F2F3 | |
| SCHEMBL7149481 | 0.89 | F7 (0.47) | F7F10PRSS1F2F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548694-B2 | Anticoagulants | HOFFMAN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1289939-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | US | disclosed |
| WO-2001090051-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | GLS, SLC6A5, GLRA1 | F7 422/4885F10 546/4885PRSS1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.